Efficacy and Safety of Tofacitinib in Pediatric Alopecia Areata: A Prospective Observational Study
May 2025
in “
Journal of Pharmacy And Bioallied Sciences
”
TLDR Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
This study evaluated the efficacy and safety of tofacitinib in 50 pediatric patients with moderate-to-severe alopecia areata over 24 weeks. Of the 45 participants who completed the study, there was a significant reduction in the Severity of Alopecia Tool (SALT) score from a mean of 66.2 to 25.7. Complete or near-complete hair regrowth was observed in 42.2% of patients, while 37.8% experienced partial regrowth. The study concluded that tofacitinib has a favorable risk–benefit profile for treating pediatric alopecia areata, suggesting JAK inhibitors as a potential therapeutic option, though further research on long-term safety and relapse rates is needed.